ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO072

Identification of Urine Apolipoprotein A-I as a Biomarker for Early Diagnosis of AKI Following Percutaneous Coronary Intervention by ITRAQ-Based Quantitative Proteomics

Session Information

Category: Acute Kidney Injury

  • 003 AKI: Clinical and Translational


  • Zhou, Fangfang, Ningbo NO.2 Hospital, Ningbo City, Zhejiang, China
  • Luo, Qun, Ningbo NO.2 Hospital, Ningbo City, Zhejiang, China
  • Shen, Gen, Ningbo NO.2 Hospital, Ningbo, Zhejiang, China
  • Ye, Honghua, Ningbo NO.2 Hospital, Ningbo, Zhejiang, China
  • Han, Lina, Ningbo NO.2 Hospital, Ningbo City, Zhejiang, China
  • Huang, Lulu, Ningbo NO.2 Hospital, Ningbo City, Zhejiang, China
  • Li, Yumei, Ningbo NO.2 Hospital, Ningbo City, Zhejiang, China
  • Wang, Zemin, Ningbo NO.2 Hospital, Ningbo City, Zhejiang, China

Acute kidney injury(AKI) has been recognized as a common complication of percutaneous coronary intervention(PCI).Our study aimed to discover and validate novel diagnostic biomarkers of acute kidney injury(AKI) following PCI by Isobaric Tags for Relative and Absolute Quantitation(ITRAQ) technology dynamically, and to explore potential mechanisms of AKI.


We performed a prospective nested case-control study. 14 older patients(>60yr) were identified with PCI-AKI. 12 patients were selected as controls, matched by age and gender. Urine were collected at different time points of pre-PCI, 6hrs, 24hrs, and 48hrs post-PCI.A training set of 56 urine samples(AKI group, n=6 and control group, n=6) were subjected to ITRAQ technology. Proteins were considered to be differentially expressed if the difference was statistically significant(p<0.05) and the fold change was >1.2 or <0.83. Differentially expressed proteins,also analyzed by bioinformatics analysis, were then investigated in a validation set of 48 urine samples (AKI group, n=8 and control group, n=6) via parallel reaction monitoring(PRM) based targeted proteomics.


A total of 14 overlapped proteins at all the different time points post-PCI showed an abundance change in AKI group as compared to those before PCI and controls. Among them, the accumulation of apolipoproteins A-I(apoA-I) were 14.86-, 18.88-, and 7.44-fold higher at 6h, 24h, and 48h post-PCI in AKI group, as compared to pre-PCI value respectively (p=0.0409, =0.0338, p=0.1009). Using the PRM approach, we successfully confirmed the differential accumulation of apoA-I at different time points post-PCI in the validation set. We also confirmed that serum level of high density lipoprotein (HDL) and apoA-I were significantly lower in AKI patients (p=0.023, p=0.047) as compared with controls. Bioinformatics analysis described that apoA-I may involved in Peroxisome Proliferator Activated Receptor(PPAR) signaling pathway.


The presence of urine apoA-I demonstrated in our study a potential diagnostic biomarker for PCI-AKI, suggesting lipid abnormalities in AKI, which may be related to HDL deficiency. Comparatively little is known regarding the role of lipids in pathogenic mechanisms of AKI, which deserve further study.


  • Government Support - Non-U.S.